Mapping The Individual Genetic Landscape of Solid Tumors With Centogene's Solid Tumor Panel
Solid tumors are diseases characterized with the formation of an abnormal mass of tissue. They can be
benign or malignant. The different types of solid tumors are named after the type of cells that form them. Examples of solid tumors are sarcomas, carcinomas, and lymphomas. Many solid tumors contain high numbers of somatic mutations, genetic changes that are not inherited but rather created within the tumor
itself. Unlike inherited “germline” mutations these somatic mutations can occur in any of the cells of the body except in the germ cells and are not transmitted to offsprings.
Genetic testing can give us the mutational profile of the solid tumor and this will in turn allow us to make better diagnostic decisions, define optimal therapeutic approaches and enhance counseling for the patient.
We firmly believe that genetic testing does not end with the technical processing of samples. This is why we place extraordinary emphasis on the medical interpretation and counseling.
The goals of somatic testing of solid tumors are to identify:
- The individual genetic landscape of the tumor by assessing multiple gene targets simultaneously
- Actionable variants within the genes known to be associated with response or resistance to specific cancer therapies
- Variants that may help to determine the prognosis for patients with solid tumors
- So far unknown variants in well described tumor genes which might be used for targeted therapies
- And to finally establish a diagnosis that will reassure both patient and physician about the occurring health problem, in order to inform and to tailor the best therapeutic strategy for the patient.
When to suggest the solid tumor panel:
The solid tumor panel can be recommended for the following patients:
- Individuals with solid tumors. The results of this test can be useful for assessing prognosis and guiding treatment of individuals with solid tumors.
- Individuals where a mutational profile from multiple genes informs diagnosis or disease stratification, prognosis or treatment options.
Benefits of solid tumorigenic testing:
- Covers 62 of the most important genes and associated mutations with 96% coverage of the coding regions
- Detects most actionable mutations with clear clinical relevance; EGFR/MAPK and PI3K pathways
- Enables rapid eligibility identification and patient stratification for clinical trials
- Allows longitudinal and serial molecular monitoring throughout the clinical trial process
- Does not require special shipping or storage provisions
- Employs expert analysis from a CLIA-certified lab
- Solid tumor panel utilizes NGS sequencing on Ion Proton Platform
- Solid tumor panel includes the following genes: ABL1, AKT1, ALK, APC, AR, ARID1A, ASXL1, ATM, AXL, BRAF, CDH1, CDK4, CDKN2A, CTNNB1, DDR2, EGFR, ERBB2, FGFR1, FGFR2, FGFR3, FGFR4, GNA11, GNAQ, GNAS, HRAS, IDH1, IDH2, JAK2, JAK3, KDM6A, KDR, KIT, KRAS, MAP2K1, MET, MLH1, MLL, MLL2, MLL3, MTOR, NF1, NOTCH1, NRAS, NTRK3, PDGFRA, PDGFRB, PIK3CA, PIK3R1, PTCH1, PTEN, PTPN11, RB1, RET, ROS1, SMAD4, SMARCA4, SMARCB1, SMO, STK11, TP53, TSC1, VHL.
- The panel covers 96% of coding regions of all 62 tumor suppressor genes and oncogenes
- Mean Coverage depth of 2,000X
- The turnaround time for the panel is 10 working days
- 10 sections of 5-10µm thickness from the FFP tissue with areas of enriched tumor clearly marked accompanied with pathology report and oncology report in case of a relapse testing
- 1µg of DNA from tumor-enriched section
- 1ml of EDTA blood or 1µg DNA from normal tissue (for example: buccal swab) as a recommended
Why choose CENTOGENE´s Solid Tumor Panel:
- We offer a short turnaround time to the best price.
- We combine medical and technical expertise.
- Our reports deliver the results in an easy and understandable way, and if needed, recommendations for additional testing are included.